Ovid Therapeutics Inc. (OVID) has 20 tenedores institucionales e internos conocidos registrados. El mayor tenedor es TAKEDA PHARMACEUTICAL CO LTD con 5,750,000 acciones. Otros tenedores destacados incluyen LEVIN JEREMY M y Werber Yaron.
En los últimos 12 meses, los internos han realizado 19 transacciones en OVID acciones — 14 compras (valoradas en $6.15M) y 2 ventas (valoradas en $29.29K). Las compras internas han superado las ventas durante este período, lo que puede señalar confianza en las perspectivas de la empresa.
OVID Participación de Insiders
Principal Titular
TAKEDA PHARMACEUTICAL CO LTD
5,750,000 acciones
Compras (12 meses)
14
$6.15M valor
Ventas (12 meses)
2
$29.29K valor
Actividad de Transacciones (12 meses)
Principales Titulares Internos
| # |
Nombre |
Cargo |
Acciones en Propiedad |
Última Declaración |
Tamaño Relativo |
| 1 |
Takeda Pharmaceutical Co Ltd |
10 Percent Owner |
5,750,000 |
2019-11-22 |
|
| 2 |
Levin Jeremy M |
Director |
957,000 |
2026-03-02 |
|
| 3 |
Werber Yaron |
Cbo, CFO, Sec. and Treas. |
131,000 |
2018-01-23 |
|
| 4 |
Daly Timothy |
EVP,finance & Corp. Controller |
125,000 |
2020-12-21 |
|
| 5 |
Haasner Dirk |
SVP, Global Regulatory Affairs |
100,000 |
2020-12-21 |
|
| 6 |
Rakhit Amit |
President and CMO |
90,983 |
2021-07-16 |
|
| 7 |
Rona Jeffrey A |
Cbfo |
88,188 |
2026-03-02 |
|
| 8 |
During Matthew |
10 Percent Owner |
75,000 |
2019-04-03 |
|
| 9 |
Bernstein Karen |
Director |
65,000 |
2026-03-02 |
|
| 10 |
Papadopoulos Stelios |
Director |
65,000 |
2026-03-02 |
|
| 11 |
Friedman Bart |
Director |
65,000 |
2026-03-02 |
|
| 12 |
Duncan Barbara Gayle |
Director |
65,000 |
2026-03-02 |
|
| 13 |
Fitzgerald Kevin Joseph |
Director |
65,000 |
2026-03-02 |
|
| 14 |
Alexander Margaret A. |
President and CEO |
61,750 |
2026-03-02 |
|
| 15 |
Ward Ana |
SVP and General Counsel |
40,000 |
2019-02-26 |
|
| 16 |
Poole Robert Michael |
Director |
30,000 |
2024-02-26 |
|
| 17 |
Tardio Jason |
Chief Operating Officer |
28,125 |
2024-02-26 |
|
| 18 |
Perone Thomas Michael |
General Counsel, Secretary |
28,125 |
2024-02-26 |
|
| 19 |
Williams Douglas E |
Director |
1,750 |
2021-05-18 |
|
| 20 |
Takeda Pharmaceuticals U.s.a., Inc. |
Director |
1,250 |
2022-07-06 |
|
Transacciones Recientes (últimos 12 meses)
| Fecha |
Nombre |
Cargo |
Tipo |
Acciones |
Precio |
Valor |
| 2026-03-23 |
Levin Jeremy M |
Executive Chairman |
Ejercicio de Opciones (Venta) |
47,333 |
$1.40 |
$66.27K |
| 2026-02-26 |
Alexander Margaret A. |
President and CEO |
Concesión de RSU |
1,435,000 |
$1.65 |
$2.37M |
| 2026-02-23 |
Alexander Margaret A. |
President and CEO |
Venta Informativa |
11,656 |
$1.45 |
$16.9K |
| 2026-02-26 |
Fitzgerald Kevin Joseph |
Director |
Concesión de RSU |
65,000 |
$1.65 |
$107.25K |
| 2026-02-26 |
Bernstein Karen |
Director |
Concesión de RSU |
65,000 |
$1.65 |
$107.25K |
| 2026-02-26 |
Friedman Bart |
Director |
Concesión de RSU |
65,000 |
$1.65 |
$107.25K |
| 2026-02-26 |
Duncan Barbara Gayle |
Director |
Concesión de RSU |
65,000 |
$1.65 |
$107.25K |
| 2026-02-26 |
Rona Jeffrey A |
Cbfo |
Concesión de RSU |
68,125 |
- |
- |
| 2026-02-23 |
Rona Jeffrey A |
Cbfo |
Venta Informativa |
8,541 |
$1.45 |
$12.38K |
| 2026-02-26 |
Levin Jeremy M |
Director |
Concesión de RSU |
957,000 |
$1.65 |
$1.58M |
| 2026-02-26 |
Papadopoulos Stelios |
Director |
Concesión de RSU |
65,000 |
$1.65 |
$107.25K |
| 2026-01-04 |
Alexander Margaret A. |
President and CEO |
Concesión de RSU |
890,000 |
$1.76 |
$1.57M |
| 2025-12-15 |
Levin Jeremy M |
CEO |
Conversión (Venta) |
71 |
- |
- |
| 2025-12-11 |
Levin Jeremy M |
CEO |
Compra Informativa |
71 |
- |
- |
| 2025-12-08 |
Takeda Pharmaceutical Co Ltd |
10 Percent Owner |
Conversión (Venta) |
1,250 |
- |
- |
| 2025-02-20 |
Fitzgerald Kevin Joseph |
Director |
Concesión de RSU |
45,000 |
$0.57 |
$25.65K |
| 2025-02-20 |
Bernstein Karen |
Director |
Concesión de RSU |
45,000 |
$0.57 |
$25.65K |
| 2025-02-20 |
Friedman Bart |
Director |
Concesión de RSU |
45,000 |
$0.57 |
$25.65K |
| 2025-02-20 |
Duncan Barbara Gayle |
Director |
Concesión de RSU |
45,000 |
$0.57 |
$25.65K |
